Hemab Therapeutics (NASDAQ:COAG) Coverage Initiated by Analysts at Wedbush

Equities research analysts at Wedbush initiated coverage on shares of Hemab Therapeutics (NASDAQ:COAG) in a report released on Tuesday, MarketBeat.com reports. The firm set an “outperform” rating and a $42.00 price target on the stock. Wedbush’s price objective points to a potential upside of 62.22% from the stock’s previous close.

COAG has been the topic of a number of other reports. The Goldman Sachs Group began coverage on Hemab Therapeutics in a report on Tuesday. They issued a “buy” rating and a $36.00 price objective on the stock. Jefferies Financial Group began coverage on Hemab Therapeutics in a report on Tuesday. They issued a “buy” rating and a $39.00 price objective on the stock. Finally, Wall Street Zen upgraded Hemab Therapeutics to a “hold” rating in a report on Saturday, May 9th. Four investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $41.75.

Hemab Therapeutics Price Performance

Shares of NASDAQ:COAG opened at $25.89 on Tuesday. Hemab Therapeutics has a 12-month low of $23.00 and a 12-month high of $36.61.

Hemab Therapeutics (NASDAQ:COAG) last issued its quarterly earnings results on Thursday, May 21st. The company reported ($23.98) earnings per share (EPS) for the quarter.

Insider Activity at Hemab Therapeutics

In related news, Director Ra Capital Management, L.P. bought 2,675,000 shares of the company’s stock in a transaction that occurred on Monday, May 4th. The shares were acquired at an average cost of $18.00 per share, for a total transaction of $48,150,000.00. Following the acquisition, the director owned 6,149,096 shares in the company, valued at $110,683,728. This represents a 77.00% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. In the last quarter, insiders bought 2,902,872 shares of company stock valued at $53,769,784.

Hemab Therapeutics Company Profile

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.